Approach to hemodynamic shock and vasopressors

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 2, 2008, Pages 546-553

  Herget Rosenthal, Stefan ^a   Saner, Fuat ^a   Chawla, Lakhmir S ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; VASOCONSTRICTOR AGENT;

ACUTE KIDNEY FAILURE; ARTICLE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG EFFECT; HUMAN; KIDNEY; PHYSIOLOGY; SHOCK;

CATECHOLAMINES; HUMANS; KIDNEY; KIDNEY FAILURE, ACUTE; SHOCK; VASOCONSTRICTOR AGENTS;

EID: 42549092570     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01820407     Document Type: Article

References (47)

1. Jimenez E: Shock. In: Critical Care, 3rd Ed., edited by Civetta JM, Taylor RW, Kirby RR, Philadelphia, Lippincott Williams & Wilkins, 1997, pp 359-387
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377, 2001
3. Weil MH, Shubin H: Proposed reclassification of shock states with special reference to distributive effects. In: The Fundamental Mechanisms of Shock, edited by Hinshaw LB, Cox BG, New York, Plenum Press, 1972, pp 13-23
4. Tabaee A, Givertz MM: Pharmacologic Management of the Hypotensive Patient. In: Irwin and Rippe's Intensive Care Medicine, 5th Ed., edited by Irwin RS, Rippe JM, Philadelphia, Lippincott Williams & Wilkins, 2003, pp 295-302
5. Trager K, DeBacker D, Radermacher P: Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9: 271-278, 2003
6. De Backer D, Creteur J, Silva E, Vincent JL: Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: Which is best? Crit Care Med 31: 1659-1667, 2003
7. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, Spies CD, Hannemann L: Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 25: 399-404, 1997
8. Martin C, Papazian L, Perrin G, Saux P, Gouin F: Norepinephrine or doparnine for the treatment of hyperdynamic septic shock? Chest 103: 1826-1831, 1993
9. Guerin JP, Levraut J, Samat-Long C, Leverve X, Grimaud D, Ichai C: Effects of dopamine and norepinephrine on systernic and hepatosplanchnic hemodynamics, oxygen exchange, and energy balance in vasoplegic septic patients. Shock 23: 18-24, 2005
10. Ledoux D, Astiz ME, Carpati CM, Rackow EC: Effects of perfusion pressure on tissue perfusion in septic shock. Crit Care Med 28: 2729-2732, 2000
11. Marik PE, Mohedin M: The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 272: 1354 -1357, 1994
12. Martin C, Viviand X, Leone M, Thirion X: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 28: 2758-2765, 2000
13. Debaveye YA, Van den Berghe GH: Is there still a place for dopamine in the modern intensive care unit? Anesth Analg 98: 461-468, 2004
14. Mullner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G: Vasopressors for shock. Cochrane Database Syst Rev (3): CDO03709, 2004
15. Reinelt H, Radermacher P, Fischer G, Geisser W, Wachter U, Wiedeck H, Georgieff M, Vogt J: Effects of a dobutamine-induced increase in splanchnic blood flow on hepatic metabolic activity in patients with septic shock. Anesthesiology 86: 818-824, 1997
16. Hiltebrand LB, Krejci V, Sigurdsson GH: Effects of dopamine, dobutamine, and dopexamine on microcirculatory blood flow in the gastrointestinal tract during sepsis and anesthesia. Anesthesiology 100: 1188-1197, 2004
17. Ralph CJ, Tanser SJ, Macnaughton PD, Sinclair DG: A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill. Intensive Care Med 28: 884-890, 2002
18. Seguin P, Laviolle B, Guinet P, Morel I, Malledant Y, Bellissant E: Dopexamine and norepinephrine versus epinephrine on gastric perfusion in patients with septic shock: A randomized study [NCT00134212]. Crit Care 10: R32, 2006
19. Renton MC, Snowden CP: Dopexamine and its role in the protection of hepatosplanchnic and renal perfusion in high-risk surgical and critically ill patients. Br J Anaesth 94: 459-467, 2005
20. Schilling T, Grundling M, Strang CM, Moritz KU, Siegmund W, Hachenberg T: Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients. Intensive Care Med 30: 1127-1133, 2004
21. Natalini G, Schivalocchi V, Rosano A, Taranto M, Pletti C, Bernardini A: Norepinephrine and metaraminol in septic shock: A comparison of the hemodynamic effects. Intensive Care Med 31: 634-637, 2005
22. De Luca L, Colucci WS, Nieminen. MS, Massie BM, Gheorghiade M: Evidence-based use of levosimendan in different clinical settings. Eur Heart J 27: 1908-1920, 2006
23. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M: Levosimendan vs; dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 297: 1883-1891, 2007
24. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietropaoli P: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 31: 638-644, 2005
25. Burger AJ: A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 11: 30-38, 2005
26. Arora RR, Venkatesh PK, Molnar J: Short and long-term mortality with nesiritide. Am Heart J 152: 1084-1090, 2006
27. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, Oz MC, Oliver JA: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95: 1122-1125, 1997
28. Morelli A, Rocco M, Conti G, Orecchioni A, De Gaetano A, Cortese G, Coluzzi F, Vernaglione E, Pelaia P, Pietropaoli P: Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 30: 597-604, 2004
29. Conger JD, Schultz MF, Miller F, Robinette JB: Responses to hemorrhagic arterial pressure reduction in different ischemic renal failure models. Kidney Int 46: 318-323, 1994
30. Molitoris BA, Sandoval R, Sutton TA: Endothelial injury and dysfunction in ischemic acute renal failure. Crit Care Med 30: S235-S240, 2002
31. Bourgoin A, Leone M, Delmas A, Garnier F, Albanese J, Martin C: Increasing mean arterial pressure in patients with septic shock: Effects on oxygen variables and renal function. Crit Care Med 33: 780-786, 2005
32. Bellorno R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356: 2139-2143, 2000
33. Friedrich JO, Adhikari N, Herridge MS, Beyene J: Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 142: 510-524, 2005
34. Bove T, Landoni G, Calabro MG, Aletti G, Marino G, Cerchierini E, Crescenzi G, Zangrillo A: Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery: A prospective, double-blind, randomized clinical trial. Circulation 111: 3230-3235, 2005
35. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, Wilensky RL, O'Neill WW: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 290: 2284-2291, 2003
36. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD: Fenoldopam mesylate in early acute tubular necrosis: A randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis 46: 26-34, 2005
37. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabro MG, Ranucci M, Zangrillo A: Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: A meta-analysis of randomized clinical trials. Am J Kidney Dis 49: 56-68, 2007
38. Morelli A, Ricci Z, Bellomo R, Ronco C, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Portieri M, Coluzzi F, Porzi P, Serio P, Bruno A, Pietropaoli P: Prophylactic fenoldopam for renal protection in sepsis: A randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 33: 2451-2456, 2005
39. Albanese J, Leone M, Garnier F, Bourgoin A, Antonini F, Martin C: Renal effects of norepinephrine in septic and nonseptic patients. Chest 126: 534-539, 2004
40. Bellomo R, Kellum JA, Wisniewski SR, Pinsky MR: Effects of norepinephrine on the renal vasculature in normal and endotoxemic dogs. Am J Respir Crit Care Med 159: 1186-1192, 1999
41. Faivre V, Kaskos H, Callebert J, Losser MR, Milliez P, Bonnin P, Payen D, Mebazaa A: Cardiac and renal effects of levosimendan, arginine vasopressin, and norepinephrine in lipopolysaccharide-treated rabbits. Anesthesiology 103: 514-521, 2005
42. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96: 576-582, 2002
43. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC Jr: Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: A double-blind placebo-controlled pilot study. Circulation 116: 1134-1138, 2007
44. Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF Jr, Luber JM Jr, Smedira NG: Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA Trial. J Am Coll Cardiol 49: 716-726, 2007
45. Witteles RM, Kao D, Christopherson D, Matsuda K, Vagelos RH, Schreiber D, Fowler MB: Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction: A randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 50: 1835-1840, 2007
46. Iglesias JI, Depalma L, Hom D, Antoniotti M, Ayoub S, Levine JS: Predictors of mortality in adult patients with congestive heart failure receiving nesiritide: Retrospective analysis showing a potential adverse interaction between neseritide and acute renal dysfunction. Nephrol Dial Transplant September 5, 2007 [epub ahead of print]
47. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111: 1487-1491, 2005